2001～2011年中国东部农村急性心肌梗死住院患者血管紧张素转化酶抑制剂和血管紧张素受体抑制剂的应用及影响因素  

ACEI/ARB use in patients hospitalized with acute myocardial infarction in eastern rural China from 2001 to 2011 and its influence factor

作　　者：关文池[1] 霍西茜[1] 白雪珂 刘佳敏[1] 李静[1] 郑昕[1] 李希[1] 张海波[1] 蒋立新[1] 

机构地区：[1]中国医学科学院北京协和医学院国家心血管病中心阜外医院国家心血管疾病临床医学研究中心心血管病国家重点实验室中国牛津国际医学研究中心,北京102308

出　　处：《中国医药导报》2017年第9期50-54,共5页China Medical Herald

基　　金：国家卫生和计划生育委员会卫生公益性行业科研专项(201202025;201502009);国家科技部科技支撑计划课题(2013BAI09B01;2015BAI12B01;2015BAI12B02)

摘　　要：目的描述中国东部农村急性心肌梗死(AMI)患者血管紧张素转化酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)2001~2011年间的使用趋势,并探讨其影响因素。方法采用两阶段随机抽样获得2001、2006、2011年具有东部农村代表性的AMI患者样本。对每年数据相应加权,以评估东部农村整体ACEI/ARB使用率和变化趋势,采用广义估计方程的多水平Logistic回归模型分析影响其使用的因素。结果研究共纳入32家医院的2760例AMI病历,其中,中国指南Ⅰ类推荐组2679例,指南Ⅱa类推荐组81例。2001、2006年和2011年,指南Ⅰ类推荐患者ACEI/ARB使用率分别为58.9%,68.3%和70.9%(趋势P值<0.01),呈上升趋势;指南Ⅱa类推荐患者为26.0%,53.2%和40.7%(趋势P值>0.05),随时间无明显改变。多因素分析显示,合并糖尿病(OR=1.42,95%CI 1.13~1.80)、高血压(OR=2.20,95%CI 1.69~2.85)、入院收缩压≥140 mm Hg(1 mm Hg=0.133 k Pa)(OR=1.78,95%CI 1.43~2.22)、左室射血分数≤40%(OR=3.95,95%CI 2.12~7.33)的患者更倾向于使用ACEI/ARB(均P<0.01);就诊于教学医院的患者ACEI/ARB使用率高于非教学医院就诊的患者(OR=3.82,95%CI 1.56~9.38,P<0.01)。结论过去的十年间,我国东部农村AMI住院患者中,Ⅰ类指征人群ACEI/ARB使用率呈逐年上升趋势,Ⅱa类人群中无明显变化。ACEI/ARB临床应用与指南推荐仍存在差距。应采取措施提高ACEI/ARB使用率,提高医疗服务质量。Objective To evaluate patterns of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers （ACEI/ARB） use in patients with acute myocardial infarction （AMI） in eastern rural China from 2001 to 2011, and identify factors affecting ACEI/ARB use. Methods A representative sample of AMI patients in eastern rural China was created from a two-stage random sampling. Regional weights were applied to estimate the rates and trend of ACEI/ARB use in eastern rural China. Multilevel Logistic regression model with generalized estimating equations was used to identify factors associated with ACEI/ARB use. Results In total, 32 hospitals were sampled and 2760 patients were included, of which 2679 were eligible for Class Ⅰ indication by Chinese guidelines and 81 were eligible for Class Ⅱ a indication. In 2001, 2006 and 2011, the use rates of ACEI/ARB for patients with Class Ⅰ indication were 58.9%, 68.3% and 70.9%, respectively （P for trend 〈 0.01）; meanwhile, there was no significant change a- mong those with Class Ⅱ a indication （26.0%, 53.2%, and 40.7%, P for trend 〉 0.05）. In Logistic regression,patients with diabetes （OR=1.42, 95%CI 1.13-1.80）, hypertension（OR=2.20, 95%CI 1.69-2.85）, systolic blood pressure ≥ 140 mmHg （1 mmHg=0.133 kPa） at admission （OR=1.78, 95%CI 1.43-2.22）, and those with an left ventricular ejec- tion fraction ≤40% （OR=3.95, 95%CI 2.12-7.33） were more likely to be treated with ACEI/ARB （all P 〈 0.01）. Those admitted to a teaching hospital had a higher likelihood to be treated with ACEI/ARB compared with those admitted to a non-teaching hospital （OR=3.82, 95%CI 1.56-9.38, P 〈 0.01）. Conclusion During the past decade in eastern rural China, the use of ACEI/ARB has increased among patients with Class Ⅰ indication, but has not changed much for Class Ⅱ a indications. Gaps still persists in clinical practice. Initiatives promoting the use of ACEI/ARB should be im- plemented to improve quality of care.

关 键 词：急性心肌梗死 血管紧张素转化酶抑制剂 血管紧张素受体阻滞剂 医疗质量 

分 类 号：R543[医药卫生—心血管疾病]